InterLymph: At the Forefront of International Lymphoma Research

InterLymph：处于国际淋巴瘤研究的前沿

• 批准号: 10252007
• 负责人: NICOLA J. CAMP
• 金额: $ 1.2万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-02 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10252007
• 关键词: Africa; Asia; Australia; Authorization documentation; Authorship; Award; Basic Science; Big Data; Businesses; Cities; Clinical Sciences; Collaborations; Communities; Country; Data; Data Coordinating Center; Development; Diagnosis; Discipline; Environment; Environmental Risk Factor; Epidemiologist; Epidemiology; Etiology; Europe; Event; Family; Food; Fostering; Foundations; France; Funding; Genealogy; Genetic; Genetic Databases; Genetic Risk; Genomics; Hodgkin Disease; Home; Immunology; Individual; Infection; Infrastructure; Institution; International; International Agency for Research on Cancer; Joints; Knowledge; Life Style; Location; Lymphoma; Lymphoproliferative Disorders; Malignant Neoplasms; Malignant lymphoid neoplasm; Manuscripts; Methods; Multiple Myeloma; National Cancer Institute; Non-Hodgkin' s Lymphoma; North America; Oceania; Oral; Outcome; Pathology; Peer Review; Play; Policies; Population; Population Genetics; Procedures; Prognosis; Prognostic Factor; Publications; Publishing; Recording of previous events; Reporting; Research; Research Personnel; Research Project Grants; Risk; Risk Factors; Role; SEER Program; Science; Scientist; Sodium Chloride; South America; Structure; Techniques; Technology; Travel; United States; Update; Utah; Work; base; biobank; career; innovation; insight; interest; lymphoid neoplasm; meetings; member; multidisciplinary; novel; organizational structure; posters; programs; study population; success; symposium; translational pipeline; volunteer; working group

ABSTRACT In 2019, an estimated 114,420 individuals in the United States alone will be diagnosed and 33,930 will die from non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) or multiple myeloma (MM). The International Lymphoma Epidemiology (InterLymph) consortium assembles researchers in epidemiology and related disciplines interested in studying these conditions. Established in 2002 with 11 members, InterLymph now boasts 81 investigators representing 57 institutions in 13 countries. It is an open scientific forum undertaking collaborative research projects to better understand risk and prognostic factors of NHL, HL and MM. Thus far, InterLymph members have successfully completed collaborative research resulting in the publication of 66 peer-reviewed manuscripts and played a significant role in several high-profile discoveries of genetic and environmental risk factors. Structured around 8 working groups, this diverse community of epidemiologists, statisticians, geneticists, basic scientists and clinicians work together to: (I) foster international collaborations; (III) develop a framework to efficiently conduct and publish collaborative studies; (II) provide a forum for the discussion, development and pursuit of new research directions; and (IV) support early career researchers. The InterLymph annual meeting, regularly attended by 40-60 investigators, is an important event to share progress of on-going research projects, maintain and expand valuable networks, plan next steps, and explore new collaborative ideas. This is achieved with oral and poster presentations and round-table discussions. In addition, local non-member experts are invited to share their expertise in an effort to stimulate new ideas, broaden perspective and strengthen our cutting-edge science. Annual meetings also provide important opportunities for junior investigators and trainees to foster professional relationships and participate in the exchange of ideas. Meeting programs and themes are developed by the InterLymph Coordinating Committee and the meeting host. The 2020 and 2021 meetings will highlight “InterLymph: At the Forefront of International Lymphoma Research”. In 2020, the meeting will be hosted in Salt Lake City, Utah, USA. Utah has a long history of successful genealogy-based studies and innovative genetic and genomic techniques. Accordingly, the InterLymph 2020 theme will be “Genealogy and Genomics”. The 2021 InterLymph meeting will be hosted in Lyon, France, the home of the International Agency for Research on Cancer. With the advent of huge population genetic databases, such as the UK biobank, the InterLymph 2021 theme will be “Big Data in Epidemiology”. Annual meetings are a proven means to maintaining collegiality and sustaining advances in joint research of lymphoid neoplasms. This conference proposal will contribute significantly to our success by providing the ability to offer travel awards and networking events, which will increase the diversity of attendees and overall value of the meetings.

摘要 2019年，仅在美国估计就有114，420人被确诊，33，930人将死于 非霍奇金淋巴瘤（NHL）、霍奇金淋巴瘤（HL）或多发性骨髓瘤（MM）。国际 淋巴瘤流行病学（InterLymph）联盟聚集流行病学和相关领域的研究人员 有兴趣研究这些条件的学科。InterLymph成立于2002年，现有11名成员， 拥有来自13个国家57个机构的81名调查员。这是一个开放的科学论坛， 合作研究项目，以更好地了解NHL，HL和MM的风险和预后因素。到目前为止， InterLymph成员成功完成了合作研究，发表了66篇 同行评审的手稿，并发挥了重要作用，在几个备受瞩目的发现，遗传和 环境风险因素。这个由流行病学家组成的多元化社区由8个工作组组成， 统计学家、遗传学家、基础科学家和临床医生共同努力：（I）促进国际合作; (III)制定一个框架，以有效地进行和出版合作研究;（二）提供一个论坛， 讨论，发展和追求新的研究方向;（IV）支持早期职业研究人员。 InterLymph年度会议定期有40-60名研究人员参加，是一个值得分享的重要事件 正在进行的研究项目的进展，维护和扩大有价值的网络，计划下一步，并探索 新的合作理念。这是通过口头和海报介绍以及圆桌讨论来实现的。在 此外，还邀请当地非成员专家分享他们的专门知识，以激发新的想法， 拓宽视野，加强我们的前沿科学。年度会议还提供重要的 初级调查员和受训人员有机会增进专业关系， 交流思想。会议方案和主题由国际淋巴协调委员会制定 和会议主持人2020年和2021年的会议将突出“InterLymph：在国际前沿” 淋巴瘤研究”。2020年，会议将在美国犹他州的湖城举办。犹他州 成功的基于系谱的研究和创新的遗传和基因组技术的历史。因此，委员会认为， InterLymph 2020的主题是“系谱学和基因组学”。2021年InterLymph会议将于 在法国的里昂，国际癌症研究机构的所在地。随着巨大的 人口遗传数据库，如英国生物银行，InterLymph 2021的主题将是“大数据在 流行病学”。年度会议是维持合议和保持在以下方面取得进展的行之有效的手段： 联合研究淋巴肿瘤。这次会议的建议将大大有助于我们的成功， 提供提供旅行奖励和网络活动的能力，这将增加 与会者和会议的整体价值。